Melanocortins form a class of regulatory peptide currently under active study; these include such biologically active substances as adrenocorticotropic hormone (ACTH) and α- β-, and γ-melanocyte-stimulating hormone (MSH). ACTH fragments, like other peptides of the melanocortins family, have marked neurotropic effects, particularly stimulating learning, memory, and attention processes. The active center of ACTH required for activation of all types of melanocortin receptor, is the sequence His-Phe-Arg-Trp and corresponds to fragment ACTH6–9. We report here studies of the synthetic peptide ACTH6–9-PGP, whose structure contains the natural fragment ACTH6–9 stabilized at the C terminal by attachment of the amino acid sequence prolyl-glycyl-proline (PGP) to increase resistance to the actions of carboxypeptidases. The effects of i.p. administration of ACTH6–9-PGP at doses of 0.5, 5, 50, 150, and 450 μg/kg as single does 15 min before assessment of anxiety levels in rats in the Vogel confl ict situation test (punished behavior) and the elevated plus maze (unpunished behavior) were studied. The effects of ACTH6–9-PGP in these tests were compared with those of its structural analog ACTH4–7-PGP at doses of 50, 150, and 450 μg/kg. The results showed that ACTH6–9-PGP in the Vogel conflict situation test increased anxiety levels in rats, which was apparent as decreases in drinking time (at all doses) and reductions in the number of licks (at doses of 0.5 and 150 μg/kg) (p < 0.01). ACTH6–9-PGP had no significant effect on the rats’ behavior in the elevated plus maze. ACTH4–7-PGP had no effects in the models of punished and unpunished behavior. Thus, ACTH6–9-PGP, in contract to ACTH4–7-PGP, was found to affect anxiety levels in rats, depending on the dose of peptide and the behavioral model used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. Catania, S. Gatti, G. Colombo, and J. M. Lipton, “Targeting melanocortin receptors as a novel strategy to control inflammation,” Pharmacol. Rev., 56, No. 1, 1–29 (2004).
A. Catania, “Neuroprotective actions of melanocortins: a therapeutic opportunity,” Trends Neurosci., 31, No. 7, 353–360 (2008).
S. V. Koroleva and N. F. Myasoedov, “Semax as a universal drug for therapy and research,” Biol. Bull., 45, No. 6, 589–600 (2018).
Y. Yang, V. J. Hruby, M. Chen, et al., “Novel binding motif of ACTH analogues at the melanocortin receptors,” Biochemistry, 48, No. 41, 9775–9784 (2009).
N. G. Levitskaya, D. A. Vilenskii, E. A. Sebentsova, et al., “Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action,” Biol. Bull., 37, No. 2, 186–192 (2010).
J. R. Holder, Z. Xiang, R. M. Bauzo, and C. Haskell-Luevano, “Structure-activity relationships of the melanocortin tetrapeptide Ac-His-D-Phe-Arg-Trp-NH2 at the mouse melanocortin receptors 4. Modifications at the Trp position,” J. Med. Chem., 45, No. 26, 5736–5744 (2002).
R. M. Dores, L. Liang, P. Davis, et al., “60 YEARS OF POMC: Melanocortin receptors: evolution of ligand selectivity for melanocortin peptides,” J. Mol. Endocrinol., 56, No. 4, T119–T133 (2016), https://doi.org/10.1530/JME-15-0292.
V. J. Hruby, B. C. Wilkes, M. E. Hadley, et al., “Alpha-melanotropin: the minimal active sequence in the frog skin bioassay,” J. Med. Chem., 30, No. 11, 2126–2130 (1987).
A. J. Clark, R. Forfar, M. Hussain, et al., “ACTH Antagonists,” Front. Endocrinol. (Lausanne), 7, 101 (2016).
A. Todorovic, C. J. Lensing, J. R. Holder, et al., “Discovery of melanocortin ligands via a double simultaneous substitution strategy based on the Ac-His-DPhe-Arg-Trp-NH2 template,” ACS Chem. Neurosci., 9, No. 11, 2753–2766 (2018).
D. Palmer, J. P. L. Gonçalves, L. V Hansen, et al., “Click-chemistrymediated synthesis of selective melanocortin receptor 4 agonists,” J. Med. Chem., 60, No. 21, 8716–8730 (2017), https://doi.org/10.1021/acs.jmedchem.7b00353.
N. G. Levitskaya, N. Yu. Glazova, E. A. Sebentsova, et al., “Nootropic and anxiolytic effects of the heptapeptide ACTH6–9Pro-Gly-Pro,” Ros. Fiziol. Zh., 105, No. 6, 761–770 (2019).
D. M. Manchenko, N. Yu. Glazova, N. G. Levitskaya, “Nootropic and analgesic effects of Semax given by different routes of administration,” Ros. Fiziol. Zh., 96, No. 10, 1014–1023 (2010).
K. V. Shevchenko, I. Y. Nagaev, V. N. Babakov, et al., “Proteolysis of His-Phe-Arg-Trp-Pro-Gly-Pro in the blood and brain of rats in vivo,” Dokl. Biochem. Biophys., 464, 301–304 (2015), https://doi.org/10.1134/S1607672915050087.
T. V. V’yunova, K. V. Shevchenko, V. P. Shevchenko, et al., “Binding of regulatory neuropeptide [3H]Semax labeled in the terminal proline residue to plasma membranes of the rat forebrain,” Neirokhimiya, 23, No. 1, 57–62 (2006).
A. N. Mironov, Guidelines for Preclinical Studies of Medicines. Part 1, Grif i K, Moscow (2012).
M. J. Millan and M. Brocco, “The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines,” Eur. J. Pharmacol., 463, 67–96 (2002).
N. G. Levitskaya and A. A. Kamenskii, “The melanocortin system,” Usp. Fiziol. Nauk., 40, No. 1, 44–65 (2009).
E. R. Duval, A. Javanbakht, and I. Liberzon, “Neural circuits in anxiety and stress disorders: a focused review,” Ther. Clin. Risk Manag., 11, 115–126 (2015).
S. Chaki, S. Ogawa, Y. Toda, et al., “Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents,” Eur. J. Pharmacol., 474, No. 1, 95–101 (2003).
J. Liu, J. C. Garza, W. Li, and X. Y. Lu, “Melanocortin-4 receptor in the medial amygdala regulates emotional stress-induced anxiety-like behaviour, anorexia and corticosterone secretion,” Int. J. Neuropsychopharmacol., 16, No. 1, 105–120 (2013).
M. Karami Kheirabad, B. Namavar Jahromi, A. Tamadon, et al., “Expression of melanocortin-4 receptor mRNA in male rat hypothalamus during chronic stress,” Int. J. Mol. Cell. Med., 4, No. 3, 182–187 (2015).
I. P. Ashmarin, Biochemistry of the Brain, St. Petersburg (1999).
X. Yia, D. S. Manickama, A. Brynskikhb, and A. V. Kabanova, “Agile delivery of protein therapeutics to CNS,” J. Control. Release, 190, 637–663 (2014).
M. B. Chauhan and N. B. Chauhan, “Brain uptake of neurotherapeutics after intranasal versus intraperitoneal delivery in mice,” J. Neurol. Neurosurg., 2, No. 1, 9 (2015).
P. D. Shabanov, “Pharmacology of peptide drugs,” Psikhofarmakol. Biol. Narkol., 8, No. 3–4, 2399–2425 (2008).
I. E. Makarenko, O. I. Avdeeva, G. V. Vanatiev, et al., “Possible pathways and volumes of administration of medicines to laboratory animals,” Mezhdunar. Vestn. Vet., 3, 78–84 (2013).
A. E. Belykh and I. I. Bobyntsev, “Delta sleep-inducing peptide: various biological effects and the mechanisms of their development,” Kursk. Nauchn. Prakt. Vestn. Chelov. Zdorov., 1, 79–90 (2016).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 106, No. 3, pp. 283–293, March, 2020.
Rights and permissions
About this article
Cite this article
Dodonova, S.A., Bobyntsev, I.I., Belykh, A.E. et al. Effects of Peptides ACTH6–9 PGP and ACTH4–7-PGP on Anxiety Levels in Rats in Punished and Unpunished Behavior. Neurosci Behav Physi 50, 1203–1208 (2020). https://doi.org/10.1007/s11055-020-01022-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-020-01022-w